Akt as a therapeutic target in cancer
Linda S. Steelman(East Carolina University), James A. McCubrey(East Carolina University), Franca Stivala(University of Catania), Massimo Libra(University of Catania), Jörg Bäsecke(University of Göttingen), Alberto M. Martelli(University of Bologna), Melchiorre Cervello(Foundation for Biomedical Research), Ferdinando Nicoletti(University of Catania), Stefan Horn(Universität Hamburg), Kristin M. Stadelman(East Carolina University), William H. Chappell(University of North Carolina at Chapel Hill)
Cited by 140
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508